Friday, October 05, 2012

Tech Stock Trading Alert: Social Media Stock Groupon (NASDAQ:GRPN) on the Move

New York, NY- October 5, 2012 (www.Investorideas.com Newswire, www.techsectorstocks.com ) Investor Ideas,, a global investor research portal for independent investors, issues a tech stock trading alert for social media stock Groupon, Inc. (NasdaqGS GRPN),  trading $5.2350, gaining   0.4350 or 9.06% as of  3:28PM EDT on over 16 Million shares. The stock had a day high of $5.37 .



Groupon, launched in November 2008 in Chicago, features a daily deal on the best stuff to do, eat, see and buy in 48 countries around the world. Groupon uses collective buying power to offer huge discounts and provide a win-win for business and consumers, delivering more than 1,000 daily deals globally. To subscribe for the best deals in your city, visit http://www.groupon.com. http://www.grouponworks.com.


About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts. Sectors include biotech stocks, tech stocks, beverage stocks, mining stocks, water, renewable energy, oil and gas.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com

Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp

Join Investor Ideas Get 14 of the best stock directories online;
Research tech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more
Join: http://www.investorideas.com/membership/


Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp

800-665-0411 - Source – www.Investorideas.com

Mining Stock Primero Mining (TSX:P) Makes TSX Top Trader List: Stock Gains over 30% On Tax Ruling

New York, New York - October 5, 2012 (Investorideas.com Mining stocks newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in sector for independent investors issues a trading alert for the top trader on the TSX for Friday morning . Primero Mining Corp (TSX: P) (NYSE:PPP) makes the top trader list , currently at $6.91, up $1.61 or 30.38% as of 12:15PM EDT on over 4 Million shares.
The stock moved on news that the Company''s Mexican subsidiary has received a positive ruling from the Mexican tax authorities (Servicio de Administración Tributaria) on its Advance Pricing Agreement ("APA") filing made in October 2011. The ruling confirms that the Company''s Mexican subsidiary appropriately records revenue and taxes from sales under the silver purchase agreement1 at realized prices rather than spot prices effective from August 6, 2010.
Investorideas.com Newswire About TSX
http://www.tmx.com/

About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts including TSX alerts
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and access our 14 online stock directories 24/7 -energy, mining stocks and more…
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Breaking Mining Stock News: SilverCrest Mines (TSX.V: SVL) (NYSE MKT:SVLC) Announces Increase in Bought Deal to $30 Million

VANCOUVER, BC - October 5, 2012 (Investorideas.com Mining Stocks Newswire) SilverCrest Mines Inc. (TSX-V:SVL)(NYSE MKT:SVLC) (the "Company"), is pleased to announce that it has entered into an amended agreement with a syndicate of underwriters led by Dundee Securities Ltd., and including Canaccord Genuity Corp. (the "Underwriters"), to purchase 11,765,000 common shares of the Company (the "Common Shares") at a price of $2.55 per Common Share for gross proceeds of $30,000,750 on a bought deal basis (the "Amended Offering").

The Company has also granted the Underwriters an over-allotment option to increase the size of the Amended Offering by up to an additional 15%, such option being exercisable in whole or in part at any time prior to 30 days after the closing of the Amended Offering.
The net proceeds from the Amended Offering will be used to eliminate the remainder of the Company's gold hedge commitments and for general corporate purposes including working capital.
Closing of the Amended Offering is anticipated to occur on or about October 30, 2012 (the "Closing Date") and is subject to the receipt of applicable regulatory approvals including approval of the TSX Venture Exchange.
The Underwriters will receive a cash commission on the Closing Date equal to 5.5% of the gross proceeds of the Amended Offering.
The Common Shares will be offered in all provinces of Canada (except Quebec) by way of a short form prospectus.
SilverCrest Mines Inc. (TSX VENTURE:SVL)(NYSE MKT:SVLC)(NYSE Amex:SVLC) is a Canadian precious metals producer headquartered in Vancouver, BC. SilverCrest's flagship property is the 100%-owned Santa Elena Mine, which is located 150 km northeast of Hermosillo, near Banamichi in the State of Sonora, Mexico. The mine is a high-grade, epithermal gold and silver producer, with an estimated life of mine cash cost of US$8 per ounce of silver equivalent (55:1 Ag:Au). SilverCrest anticipates that the 2,500 tonnes per day facility should recover approximately 4,805,000 ounces of silver and 179,000 ounces of gold over the 6.5 year life of the open pit phase of the Santa Elena Mine. A three year expansion plan is underway to double metals production at the Santa Elena Mine and exploration programs are rapidly advancing the definition of a large polymetallic deposit at the La Joya property in Durango State.
FORWARD-LOOKING STATEMENTS
This news release contains "forward-looking statements" within the meaning of Canadian securities legislation and the United States Securities Litigation Reform Act of 1995. Such forward-looking statements concern the Company's anticipated results and developments in the Company's operations in future periods, planned exploration and development of its properties, plans related to its business and other matters that may occur in the future. These statements relate to analyses and other information that are based on expectations of future performance, including silver and gold production and planned work programs. Statements concerning reserves and mineral resource estimates may also constitute forward-looking statements to the extent that they involve estimates of the mineralization that will be encountered if the property is developed and, in the case of mineral reserves, such statements reflect the conclusion based on certain assumptions that the mineral deposit can be economically exploited.
Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors which could cause actual events or results to differ from those expressed or implied by the forward-looking statements, including, without limitation: risks related to precious and base metal price fluctuations; risks related to fluctuations in the currency markets (particularly the Mexican peso, Canadian dollar and United States dollar); risks related to the inherently dangerous activity of mining, including conditions or events beyond our control, and operating or technical difficulties in mineral exploration, development and mining activities; uncertainty in the Company's ability to raise financing and fund the exploration and development of its mineral properties; uncertainty as to actual capital costs, operating costs, production and economic returns, and uncertainty that development activities will result in profitable mining operations; risks related to reserves and mineral resource figures being estimates based on interpretations and assumptions which may result in less mineral production under actual conditions than is currently estimated and to diminishing quantities or grades of mineral reserves as properties are mined; risks related to governmental regulations and obtaining necessary licenses and permits; risks related to the business being subject to environmental laws and regulations which may increase costs of doing business and restrict our operations; risks related to mineral properties being subject to prior unregistered agreements, transfers, or claims and other defects in title; risks relating to inadequate insurance or inability to obtain insurance; risks related to potential litigation; risks related to the global economy; risks related to the Company's status as a foreign private issuer in the United States; risks related to all of the Company's properties being located in Mexico and El Salvador, including political, economic, social and regulatory instability; and risks related to officers and directors becoming associated with other natural resource companies which may give rise to conflicts of interests. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in the forward-looking statements. The Company's forward-looking statements are based on beliefs, expectations and opinions of management on the date the statements are made. For the reasons set forth above, investors should not place undue reliance on forward-looking statements.
The information provided in this news release is not intended to be a comprehensive review of all matters and developments concerning the Company. It should be read in conjunction with all other disclosure documents of the Company. The information contained herein is not a substitute for detailed investigation or analysis. No securities commission or regulatory authority has reviewed the accuracy or adequacy of the information presented.
J. Scott Drever, President
SILVERCREST MINES INC.
Contact:
SilverCrest Mines Inc.
Fred Cooper
(604) 694-1730 ext. 108
Toll Free: 1-866-691-1730
(604) 694-1761 (FAX)
info@silvercrestmines.com
www.silvercrestmines.com
Disclaimer: Investorideas.com does not make stock recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. Silvercrest Mines has compensated Investorideas for annual news publication and distribution and company profile: nine thousand seven hundred starting August 2012
More info: www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Mining Stock News: SilverCrest Mines (TSX.V: SVL) (NYSE MKT:SVLC) Announces $26.1 Million Bought Deal

VANCOUVER, BC - October 5, 2012 (Investorideas.com Mining Stocks Newswire) SilverCrest Mines Inc. (TSX-V:SVL)(NYSE MKT:SVLC) (the "Company"), is pleased to announce that it has entered into an agreement with a syndicate of underwriters led by Dundee Securities Ltd., and including Canaccord Genuity Corp. (the "Underwriters"), to purchase 10,235,000 common shares of the Company (the "Common Shares") at a price of $2.55 per Common Share for gross proceeds of $26,099,250 on a bought deal basis (the "Offering").

The Company has also granted the Underwriters an over-allotment option to increase the size of the Offering by up to an additional 15%, such option being exercisable in whole or in part at any time prior to 30 days after the closing of the Offering.
The net proceeds from the Offering will be used to eliminate the remainder of the Company's gold hedge commitments and for general corporate purposes including working capital.
Closing of the Offering is anticipated to occur on or about October 30, 2012 (the "Closing Date") and is subject to the receipt of applicable regulatory approvals including approval of the TSX Venture Exchange.
The Underwriters will receive a cash commission on the Closing Date equal to 5.5% of the gross proceeds of the Offering.
The Common Shares will be offered in all provinces of Canada (except Quebec) by way of a short form prospectus.
SilverCrest Mines Inc. (TSX VENTURE:SVL)(NYSE MKT:SVLC)(NYSE Amex:SVLC) is a Canadian precious metals producer headquartered in Vancouver, BC. SilverCrest's flagship property is the 100%-owned Santa Elena Mine, which is located 150 km northeast of Hermosillo, near Banamichi in the State of Sonora, Mexico. The mine is a high-grade, epithermal gold and silver producer, with an estimated life of mine cash cost of US$8 per ounce of silver equivalent (55:1 Ag:Au). SilverCrest anticipates that the 2,500 tonnes per day facility should recover approximately 4,805,000 ounces of silver and 179,000 ounces of gold over the 6.5 year life of the open pit phase of the Santa Elena Mine. A three year expansion plan is underway to double metals production at the Santa Elena Mine and exploration programs are rapidly advancing the definition of a large polymetallic deposit at the La Joya property in Durango State.
FORWARD-LOOKING STATEMENTS
This news release contains "forward-looking statements" within the meaning of Canadian securities legislation and the United States Securities Litigation Reform Act of 1995. Such forward-looking statements concern the Company's anticipated results and developments in the Company's operations in future periods, planned exploration and development of its properties, plans related to its business and other matters that may occur in the future. These statements relate to analyses and other information that are based on expectations of future performance, including silver and gold production and planned work programs. Statements concerning reserves and mineral resource estimates may also constitute forward-looking statements to the extent that they involve estimates of the mineralization that will be encountered if the property is developed and, in the case of mineral reserves, such statements reflect the conclusion based on certain assumptions that the mineral deposit can be economically exploited.
Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors which could cause actual events or results to differ from those expressed or implied by the forward-looking statements, including, without limitation: risks related to precious and base metal price fluctuations; risks related to fluctuations in the currency markets (particularly the Mexican peso, Canadian dollar and United States dollar); risks related to the inherently dangerous activity of mining, including conditions or events beyond our control, and operating or technical difficulties in mineral exploration, development and mining activities; uncertainty in the Company's ability to raise financing and fund the exploration and development of its mineral properties; uncertainty as to actual capital costs, operating costs, production and economic returns, and uncertainty that development activities will result in profitable mining operations; risks related to reserves and mineral resource figures being estimates based on interpretations and assumptions which may result in less mineral production under actual conditions than is currently estimated and to diminishing quantities or grades of mineral reserves as properties are mined; risks related to governmental regulations and obtaining necessary licenses and permits; risks related to the business being subject to environmental laws and regulations which may increase costs of doing business and restrict our operations; risks related to mineral properties being subject to prior unregistered agreements, transfers, or claims and other defects in title; risks relating to inadequate insurance or inability to obtain insurance; risks related to potential litigation; risks related to the global economy; risks related to the Company's status as a foreign private issuer in the United States; risks related to all of the Company's properties being located in Mexico and El Salvador, including political, economic, social and regulatory instability; and risks related to officers and directors becoming associated with other natural resource companies which may give rise to conflicts of interests. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in the forward-looking statements. The Company's forward-looking statements are based on beliefs, expectations and opinions of management on the date the statements are made. For the reasons set forth above, investors should not place undue reliance on forward-looking statements.
The information provided in this news release is not intended to be a comprehensive review of all matters and developments concerning the Company. It should be read in conjunction with all other disclosure documents of the Company. The information contained herein is not a substitute for detailed investigation or analysis. No securities commission or regulatory authority has reviewed the accuracy or adequacy of the information presented.
J. Scott Drever, President
SILVERCREST MINES INC.
Contact:
SilverCrest Mines Inc.
Fred Cooper
(604) 694-1730 ext. 108
Toll Free: 1-866-691-1730
(604) 694-1761 (FAX)
info@silvercrestmines.com
www.silvercrestmines.com
Disclaimer: Investorideas.com does not make stock recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. Silvercrest Mines has compensated Investorideas for annual news publication and distribution and company profile: nine thousand seven hundred starting August 2012
More info: www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings a

Thursday, October 04, 2012

TSX Top Trader: Precious Metal Stock Sulliden Gold (TSX:SUE) Leads Volume and Gains over 13%

New York, New York - October 4, 2012 (www.investorideas.com newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in sector for independent investors issues a trading alert for the top trader on the TSX for Thursday morning; Sulliden Gold Corporation Ltd. (TSX:SUE.TO), trading at $1.06, gaining 0.13 or 13.98% as of 11:06AM EDT on over 9.8 Million shares. The stock had a morning high of $1.07.
The stock moved after the Company announced that based on discussions with its shareholders, it will not be proceeding with the milestone bonus plan outlined in the Management Information Circular dated September 5, 2012.
Investorideas.com Newswire Sulliden Gold Corporation Ltd. is a Canadian precious metals company focused on the exploration and development of its wholly owned Shahuindo Gold and Silver Project, located in a prolific gold producing district in northern Peru. Sulliden is listed on the Toronto (TSX) and Lima (BVL) stock exchanges under the symbol SUE, as well as the premier tier of the U.S. Over-the-Counter (OTC) market (OTCQX) under the symbol SDDDF. www.sulliden.com.
About TSX

http://www.tmx.com/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts including TSX alerts
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and access our 14 online stock directories 24/7 -energy, mining stocks and more…
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Natural Gas Vehicle Stocks Trading Alert: CLNE, QTWW, WPRT

New York, New York - October 4, 2012 (Investorideas.com newswire, www.naturalgasstocks.com) Investorideas.com staff: Investorideas.com, an investor research portal specializing in sector for independent investors issues a sector snapshot for natural gas vehicle stocks for October 4th. Quantum Fuel Systems leads the group following news on a Fisker contract.

Clean Energy Fuels (NASDAQ:CLNE) is trading at $13.74, up 0.58 or 4.41% as of 10:50AM EDT on over 400,000 shares.
Quantum Fuel Systems (NASDAQ:QTWW) is trading 6.12%, at 0.83, gaining 0.0479 as of 10:46AM EDT on over 160,000 shares. The Company reported today that it has been awarded a new development contract from Fisker Automotive for advanced product development on the Fisker Karma. Under the contract, Quantum will continue to develop advanced features for the Fisker Karma vehicle to enable future product upgrades.
Westport Innovations Inc. (NASDAQ: WPRT) (TSX: WPT) is trading at $31.47, up 0.80(2.61%) on over 600,000 shares as of 10:58AM EDT, with a morning high of $31.75.
Investorideas.com Newswire Research more natural gas stocks at the Investorideas stock directory of publicly traded stocks
http://www.investorideas.com/Companies/NaturalGas/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and access our 14 online stock directories 24/7 - water, renewable energy, mining stocks and more…
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

App News: INVESTORIDEAS.COM OFFERS INVESTOR RELATIONS APP TO PUBLIC COMPANIES

NEW YORK - October 4, 2012 (www.investorideas.com newswire) InvestorIdeas.com, a leading website that provides the best of services and investment tools for companies and investors with regard to stock research by sector, announced today the offering of InvestorIdeas.com Mobile. InvestorIdeas.com Mobile is powered by theIRapp™ and allows publicly traded companies to optimize their investor relations content for iPhone, iPad and Android mobile devices. InvestorIdeas.com Mobile is part of theIRapp™ white label partner program.

Dawn Vanzant, president of InvestorIdeas.com said, "At InvestorIdeas.com, we realize the importance of mobile to the way in which public companies are now expected to communicate as well as to the way in which investors consume IR related information. theIRapp's turn-key solution allows companies to optimize their IR content for all of the important mobile devices – iPhone, iPad and Android – which represent more than 80% of the worldwide mobile market. And they can now do this in a timely (less than 3 weeks) and extremely cost effective way.”
"We are excited to be the IR app engine behind InvestorIdeas.com Mobile. By subscribing to theIRapp through InvestorIdeas.com, any public company can offer an IR app to its current and prospective investors through which to distribute press releases, corporate materials, presentations, videos, archived conference calls and any other communications content,” said Jeff Corbin, co-founder of theIRapp.
InvestorIdeas.com Mobile , powered by theIRapp™, offers features that include:
  • Push notifications alerting investors when new information is available
  • Investor sign-up for company information
  • Investor email opt-in
  • Information sharing via social media channels and email
  • Automated, real-time stock price information (through live data feeds)
  • Automated posting of newswire released press releases
  • Immediate downloads of SEC filings
  • Video streaming
  • Audiocast conference call streaming
  • Corporate materials such as fact sheets, presentations, or marketing materials
  • Analyst coverage
  • Listings of upcoming Events
  • Company contact information
To subscribe to InvestorIdeas.com Mobile go to www.investorideas.com or www.theIRapp.com. Be sure to mention InvestorIdeas.com when subscribing.
About InvestorIdeas.com
InvestorIdeas.com is a leader in investor stock research with a focus on energy and water . Sectors covered include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech, China stocks and agriculture.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
About theIRapp™ Partner Program
theIRapp™ offers organizations that serve publicly traded companies the ability to private label theIRapp™ and offer their customers and clients the value-added service of optimizing their IR content for mobile devices. By partnering with theIRapp™, companies can showcase their corporate identity and brand logo as "powered by theIRapp™.”
About theIRapp™
theIRapp™ ( www.theIRapp.com) is a turnkey mobile investor relations application building solution available to all publicly traded companies. It enables a company's investor relations information to be downloaded via Apple's App Store on the iPhone and iPad as well as Google Play for Android devices. theIRapp™ is a simple way for investors to engage with critical company and stock information. theIRapp™ delivers easy sharing of content with colleagues and friends as a next generation IR solution for establishing transparency, building shareholder loyalty, and expanding an investor following.
By providing a company's ticker symbol and logo, a public company can have its own customized app available as a free download across millions of investors within a matter of weeks. Through theIRapp™, retail and institutional investors have access to automated, real-time stock price information (via live data feeds), press releases, SEC filings, analyst coverage, corporate documents (fact sheets, presentations, etc.), videos, audiocast conference calls, upcoming events and company contact information.
Contact:
InvestorIdeas.comtheIRapp, LLC
Dawn Vanzant Jeff Corbin
800-665-0411212-896-1214
dvanzant@investorideas.comjcorbin@theIRapp.com
www.investorideas.comwww.theIRapp.com

Wednesday, October 03, 2012

NASDAQ Top Gainer Sarepta Therapeutics (NASDAQ:SRPT) Spikes 182%

New York, New York - October 3, 2012 (www.investorideas.com newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in sector for independent investors issues a trading alert for NASDAQ’s top percentage gainer, Sarepta Therapeutics (NASDAQ:SRPT), up a whopping 182% . The stock is trading at $42.32, moving 27.33 or 182.32% as of 2:25PM EDT on over 23 Million shares.

The Company today reported that treatment with its lead exon-skipping compound, eteplirsen, met the primary efficacy endpoint, increase in novel dystrophin, and achieved a significant clinical benefit on the primary clinical outcome, the 6-minute walk test (6MWT) over the placebo/delayed treatment cohort in a Phase IIb extension trial in Duchenne muscular dystrophy (DMD) patients.
Eteplirsen administered once weekly at either 30 mg/kg or 50 mg/kg for 48 weeks (n=8) resulted in a statistically significant increase (p≤0.001) in dystrophin-positive fibers to 47.0% of normal. The placebo/delayed treatment cohort, which had received 24 weeks of eteplirsen at either 30 mg/kg or 50 mg/kg following 24 weeks of placebo (n=4), also showed a statistically significant increase in dystrophin-positive fibers to 38.3% of normal (p≤0.009).
Full news:
http://finance.yahoo.com/ news/ sarepta-therapeutics- announces- eteplirsen-meets- 110000135.html
Investorideas.com Newswire Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. www.sareptatherapeutics.com.
About NASDAQ
http://www.nasdaq.com/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and access our 14 online stock directories 24/7 - water, renewable energy, mining stocks and more…
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

How to Find the next potential big stock winner in your favorite sector!

New York, New York - October 3, 2012 (Investorideas.com water newswire, www.water-stocks.com) Investorideas.com staff: Investorideas.com, an investor research portal specializing in sector for independent investors has updated its fourteen global stock directories for October. Smart money is looking at water stocks but there are winners in every sector and sometimes within the small and microcap stocks.

In a recent Investorideas.com article , water investment expert Neil Berlant named his potential long term beneficiaries based on global drought conditions: "BMI, CCC, ERII, HEK, ITRI, LAYN, LNN, MWA, NWPX, TTC, VMI." http://www.investorideas.com/news/2012/water/09281.asp
"Our water stocks directory has just been updated for October, as well as all others in our portfolio. We just added beverage and food stocks to our portfolio and we are just in the process of updating our gaming stocks directory, so it will be added shortly. When social networking stocks and cloud computing stocks became hot, we added them for our members" noted founder Dawn Van Zant.
"We find it's not just retail investors that buy our directories and become members, it's also institutions that find them a resource as well, when researching a sector. "
The current list of 14 directories includes stocks on the TSX, OTC, NASDAQ, NYSE as well as global stock exchanges. The list of directories include Renewable Energy Stocks Directory,
Mining and Gold Stocks Directory, Water Stocks Directory
Coal Stocks Directory, Environment/Lohas Stocks Directory, Biotech Stocks Directory, Fuel Cell Stocks Directory, Nanotechnology Stocks Directory, Natural Gas Stocks Directory, Defense Stocks Directory, Oil and Gas Stocks Directory, Agriculture Stocks Directory, China Stocks Directory and the Beverage Stocks Directory.
How to become a member and access our 14 online stock directories 24/7 - water, renewable energy, mining stocks and more…
http://www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Biotech Stock News; Aethlon Medical (OTCBB: AEMD) Releases EXOSOMES & MICROVESICLES 2012 Presentation

SAN DIEGO - October 3, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), today released the slide-deck underlying a presentation given yesterday by its Chairman and CEO, Jim Joyce at the EXOSOMES & MICROVESICLES 2012 conference in Orlando, Florida. The presentation was entitled: Extracorporeal clearance of tumor-secreted exosomes as an adjunct to enhance cancer therapy efficacy.
Investorideas.com Newswire
The presentation focused on the potential of the Aethlon Hemopurifier® to be combined with chemo and immunotherapies as a strategy to enhance cancer therapy outcomes. The Hemopurifier®, which is a first-in-class device being advanced in Hepatitis C (HCV) care, has also demonstrated the ability to capture cancer-promoting exosomes secreted by tumors. Tumor-secreted exosomes have emerged to become a potentially vital therapeutic target in cancer as researchers have reported these microvesicular particles promote tumor progression by inducing programmed cell death of anti-cancer immune cells. As a result of inhibiting the immune response, exosomes increase the proliferation and spread of many forms of cancer. Researchers have also reported that exosomes seed the spread of metastasis, promote angiogenesis (essential for tumor survival and growth), increase tumor aggressiveness, and contribute to anti-cancer drug resistance.
The slide-deck of the presentation can be accessed on the Aethlon Medical website here

About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs

Tuesday, October 02, 2012

TSX Tech Stock Trading Alert: Research In Motion (TSX: RIM) Makes Top Trading List

New York, NY - October 2, 2012 (Investorideas.com newswire, www.techsectorstocks.com) Investor Ideas,, a global investor research portal for independent investors, issues a tech stock trading alert for Research In Motion Limited (NASDAQ: RIMM), (TSX:RIM). The stock made the top ten traders list on the TSX, trading at $ 8.240, up 0.550 or 7.15% on 5,781,777 shares.
The company reported second quarter earnings last week.
Investorideas.com Newswire
About Research In Motion
Research In Motion (RIM), a global leader in wireless innovation, revolutionized the mobile industry with the introduction of the BlackBerry(R) solution in 1999. Today, BlackBerry products and services are used by millions of customers around the world to stay connected to the people and content that matter most throughout their day. Founded in 1984 and based in Waterloo, Ontario, RIM operates offices in North America, Europe, Asia Pacific and Latin America. RIM is listed on the NASDAQ Stock Market (RIMM) and the Toronto Stock Exchange (RIM.TO). For more information, visit www.rim.com or www.blackberry.com.
About TSX
http://www.tmx.com/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts. Sectors include biotech stocks, tech stocks, beverage stocks, mining stocks, water, renewable energy, oil and gas.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas Get 14 of the best stock directories online;
Research tech stocks, oil and gas stocks, gold stocks, water stocks, renewable energy stocks and more
Join: http://www.investorideas.com/membership/
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
800-665-0411 - Source - www.Investorideas.com

Biotech Stock Breaking News; Aethlon Medical (OTCBB: AEMD) Releases Hepatitis C Virus (HCV) Treatment Protocol and Inclusion/Exclusion Criteria Underlying Compassionate-Use Commercialization Program

SAN DIEGO - October 2, 2012 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, today released the treatment protocol underlying a program that will provide hard-to-treat HCV-infected individuals with expanded access to Hemopurifier® therapy. The Company also disclosed inclusion and exclusion criteria for candidate patients as well as details on the physicians who will administer the program, which is expected to generate first product sales of the Aethlon Hemopurifier®.
Investorideas.com Newswire
The Aethlon Hemopurifier® is a first-in-class medical device with broad-spectrum capability to address infectious viral pathogens and immunosuppressive exosomes underlying cancer and other life-threatening conditions. In the expanded access program, Hemopurifier® therapy will be administered to selectively target the rapid clearance of HCV from the entire circulatory system to improve benefit, dose, duration and tolerability of standard-of-care drug therapy. The program is being initiated with support from the Institutional Review Board at the Medanta Medicity Institute (Medicity) to allow compassionate usage of the Aethlon Hemopurifier® for individuals who previously failed or subsequently relapsed standard-of-care drug regimens. The Medicity is a leading center for medical tourism in India.
In addition to offering Hemopurifier® therapy to the citizens of India, HCV-infected individuals from the United States, European Union and other regions of the world may pursue treatment through the expanded access program. It is estimated that approximately 170 million people worldwide are infected with HCV, which leads to chronic liver disease or cirrhosis, and is a leading cause of liver transplantation.
"We are grateful for the opportunity to provide hard-to-treat HCV-infected individuals with access to Hemopurifier® therapy," stated Aethlon Chairman and CEO, Jim Joyce. "Beyond advancing our therapeutic objectives, the resulting Hemopurifier® product sales will augment the government contract revenue stream we established this past year."

The Medicity Expanded Access Treatment Protocol
The Medicity expanded access program will offer HCV-infected individuals the option of either a 3-day or 7-day Hemopurifier® therapy regimen. Under each regimen, Hemopurifier® therapy will be administered continuously for a period up to six hours on each treatment day. While there will be a difference in cost, Hemopurifier® therapy underlying both regimens will be initiated in combination with standard-of-care drug therapy. The treatment objective will be to accelerate the rate and increase the likelihood that patients achieve undetectable HCV RNA. Details related to therapy pricing and candidate patient enrollment processes at the Medicity are anticipated in the coming weeks.
Candidate Patient Inclusion Criteria
  • Males or females 18 years of age and older testing positive for any HCV genotype
  • HCV-infected individuals that have relapsed after completing a previous course of standard-of-care drug therapy
  • Null responders or individuals who previously were unable to achieve > 2 log viral load reduction at month three of standard of care drug therapy
  • Candidate patients must be willing to submit to temporary vascular access catheterization
  • Ability to tolerate blood volume losses of up to 150 ml per week
  • Stable clinical condition, including stable hematocrit
  • Individuals on ACE inhibitors must suspend ACE inhibitor administration for a minimum of six days prior to initiating therapy
  • Karnofsky score = 60
  • Details of blood chemistry inclusion criteria will be provided to candidate patients who meet the above criteria
  • Candidate patients will be required to sign a written informed consent prior to enrollment in the treatment access program
Candidate Patient Exclusion Criteria
  • Clinically significant infection, other than HCV, defined as any acute viral, bacterial, or fungal infection, which requires specific therapy (Anti-infectious therapy must have been completed at least 14-days before entry into study)
  • Co-infections with Hepatitis B virus and Human immunodeficiency virus (HIV)
  • Received any investigational drug agent(s) within 28-days of entry into study
  • Any known pre-existing medical condition that could interfere with the subject's participation in the protocol, including serious psychiatric disorders, CNS trauma or active seizure disorders requiring medication, poorly controlled diabetes mellitus, significant cardiovascular dysfunction within the past 6 months (e.g., angina, congestive heart failure, recent myocardial infarction, severe hypotension, or significant arrhythmia)
  • Subjects with ECG showing clinically significant abnormalities
  • Need for frequent blood transfusions.
  • Recent History of bleeding or bleeding disorders requiring the restriction in use of anticoagulants during study treatments.
  • Active immunologically mediated disease (e.g., inflammatory bowel disease [Crohn's disease, ulcerative colitis], rheumatoid arthritis, idiopathic thrombocytopenia purpura, systemic lupus erythematosus, autoimmune or inherited hemolytic anemia, scleroderma, severe psoriasis)
  • Any medical condition requiring, or likely to require during the course of the study, chronic systemic administration of steroids or other immune-regulatory medications
  • Substance abuse, such as alcohol (~80 gm/day), IV drugs, and inhaled drugs (If the subject has a history of substance abuse, to be considered for inclusion into the protocol, the subject must have abstained from using the abused substance for at least 2 months
  • Any cancer requiring systemic chemotherapy
  • Any other condition that, in the opinion of the principal investigators or treating physicians, would make the subject unsuitable for enrollment, or could interfere with the subject participating in and completing the expanded access protocol
Current HCV Studies
In addition to the forthcoming expanded access program, Aethlon has been conducting a study at the Medicity which is evaluating the capability of the Aethlon Hemopurifier® to accelerate HCV RNA depletion at the outset of standard of care peginterferon+ribavirin (PR) therapy. Specifically, HCV-infected individuals are enrolled to receive up to three, six-hour Hemopurifier® treatments during the first three days of PR drug therapy. Aethlon recently reported that two HCV-infected patients who received Hemopurifier® therapy in combination with PR drug therapy achieved undetectable viral load at day-7, which is rarely reported in drug therapy alone.
A primary clinical endpoint of the Medicity protocol has been to increase the incidence of rapid virologic response (RVR), defined as undetectable HCV RNA at day 30 of therapy. RVR represents the clinical endpoint that best predicts treatment cure, otherwise known as sustained virologic response (SVR), defined as undetectable HCV RNA 24-weeks after the completion of PR drug therapy. As a point of reference, the landmark IDEAL Study of 3,070 HCV genotype-1 patients documented that only 10.35% (n=318/3070) of PR treated patients achieved a RVR. However, patients that achieved a RVR had SVR rates of 86.2% (n=274/318) versus SVR rates of 32.5% (n=897/2752) in non-RVR patients. While the incidence of undetectable HCV RNA at day-7 is not reported in the IDEAL study, the study did reveal that just 4.3% (n=131/3070) of patients achieved undetectable HCV RNA at day-14, which equated to a 91% (n=118/131) SVR rate.
Aethlon reported that Hemopurifier® therapy has been well tolerated and without device-related adverse events in ten treated patients. Of these ten patients, seven patients were infected with HCV genotype-1; two patients were infected with HCV genotype-3; and one patient was infected with HCV genotype-5. At present, undetectable HCV RNA is reported in eight of the 10 treated patients. Of the two patients with detectable HCV RNA, one discontinued PR therapy as a result of a diabetes related condition. HCV RNA is undetectable in all patients (n=4) that have been monitored for 48 weeks since receiving Hemopurifier® therapy. Among the 10 treated patients, Aethlon reported that six genotype-1 patients received the three treatment Hemopurifier® protocol, which resulted in four (67%) patients achieving a RVR. The IDEAL study predicts it would normally require approximately 40 PR treated patients to achieve 4 RVR outcomes. Both patients who achieved undetectable HCV RNA at day-7 also achieved a RVR. Beyond the high likelihood of a SVR, genotype-1 patients that achieve a RVR also have the opportunity to reduce the duration of PR drug therapy from 48 weeks to 24 weeks.
About Medanta – The Medicity
Medanta – The Medicity is one of India's largest multi-super specialty institutes located in Gurgaon, a bustling town in the National Capital Region. Founded by eminent cardiac surgeon, Dr. Naresh Trehan, the institution has been envisioned with the aim of bringing to India the highest standards of medical care along with clinical research, education and training. Medanta is governed under the guiding principles of providing medical services to patients with care, compassion and commitment.
Spread across 43 acres, the institute includes a research center, medical and nursing school. It has 1250 beds and over 350 critical care beds with 45 operation theatres catering to over 20 specialties. Medanta houses six centers of excellence, which provide medical intelligentsia, cutting-edge technology and state-of-the-art infrastructure with a well-integrated and comprehensive information system. The Medicity brings together an outstanding pool of doctors, scientists and clinical researchers to foster collaborative, multidisciplinary investigation, inspiring new ideas and discoveries; and translating scientific advances more swiftly into new ways of diagnosing and treating patients and preventing diseases. A one-of-its-kind facility across the world, Medanta through its research integrates modern and traditional forms of medicine to provide accessible and affordable healthcare.
The Medicity Expanded Access Program Physicians
Dr. Vijay Kher - Chairman, Division of Nephrology, Kidney & Urology Institute
Dr. Vijay Kher is currently Chairman, Division of Nephrology, Medanta Kidney & Urology Institute. Dr. Kher has established Academic & Clinical departments of Nephrology at Shere-Kashmir, Institute of Medical Sciences in Srinagar, SGPGIMS Lucknow, Apollo Hospitals, New Delhi, Fortis group of hospitals NCR, Delhi & now at Medanta. His research interests are kidney transplantation (clinical immunosuppression, pre emptive kidney transplantation & steroid free immunosuppression, cost-containment), progression of renal disease, acute kidney injury and glomerulonephritis. An astute clinician, a teacher par excellence and a keen researcher, Dr. Kher combines these assets with a friendly and inclusive demeanor to inspire the Nephrology fraternity in India by his professional dedication, academic excellence and social responsibility. He has been awarded fellowships of National Academy of Medical Sciences, Royal College of Physicians Edinburg & Indian Society of Nephrology. Dr. Kher has published more than 150 papers in peer-reviewed journals, 24 book chapters and has edited 5 books.
Dr. Randhir Sud - Chairman, Medanta Institute of Digestive & Hepatobiliary Sciences
Dr. Sud is Chairman of The Medanta Institute of Digestive & Hepatobiliary Sciences, which is a dedicated facility for patients with gastrointestinal, liver, pancreatic and biliary diseases, There are multiple treatment options for a disease and to provide the best available treatment to patients, this Institute has devised protocols where medical, surgical and allied teams jointly decide patient treatments and management.
About Aethlon Medical
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Marc Robins
877.276.2467
mr@aethlonmedical.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page on Investorideas.comDisclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) Investorideas.com is paid by AEMD to publish news and distribute content through Investordeas.com Newswire and its syndicated partners and blogs

Entertainment News: Rhode Island filmmaker Chad A. Verdi's film LOOSIES premieres on Showtime Oct 4th

EAST GREENWICH, RI - October 2, 2012 (Investorideas.com Newswire) Verdi Productions and the Woodhaven Production Company are pleased to announce the cable premiere of their film Loosies. Loosies will be shown worldwide by the Showtime network starting Oct 4th. Showtime acquired the paid cable rights earlier this year. Screen Media of NY has acquired Verdi's latest two films, Infected and Self-Storage. Infected will premiere at Rock and Shock on Oct 13th and will hit select theaters on Oct 25th. A special sneak peek of Self Storage will follow the Infected premiere and be released in select theaters in the first quarter of 2013.

Loosies, which was released theatrically earlier this year by IFC, tells the story of Bobby (Peter Facinelli), a NYC pickpocket passing as a Wall Street stockbroker who roams the city looking for marks. He must face reality when an old fling informs him she's pregnant, and the baby is his. Suddenly, two different worlds collide, forcing Bobby to reevaluate a lifetime of missteps, and make a big decision about his future.
The film stars Peter Facinelli (Twilight, Nurse Jackie, The Scorpion King), Jaimie Alexander (Thor, Rest Stop, Hallowed Ground), Vincent Gallo (Buffalo '66, The Brown Bunny, Tetro), Michael Madsen (Reservoir Dogs, Kill Bill Vol. 1 & 2), and Joe Pantoliano (Memento, The Matrix, The Fugitive). The original soundtrack was composed and performed by Paul McDonald (American Idol), an original score by Chad Fischer ( Garden State ), and music supervision by Michelle Verdi, head of music and talent for both Verdi Productions and the Woodhaven Production Company.
Infected, a horror/zombie thriller set in the woods of New England, centers around Terry, an absentee father (Michael Madsen), and his son Andrew (Tom DeNucci -Inkubus, Loosies) who must fight for survival when their small, close-knit hunting group becomes infected with a virus that originated from a rabid deer they killed and consumed. This infection causes the crew, including Doctor Denehey (William Forsythe), to become homicidal and violent and gives them an insatiable, cannibalistic thirst for humans. In this modern day Night of The Living Dead, the father and son duo are forced to relinquish old friendships as their former hunting buddies become... Infected.
Self Storage, written by Rhode Island actor/writer/producer Tom DeNucci (Inkubus, Loosies, Infected), tells the story of Jake, the night watchman working at a highly secured self storage facility. His pals are home from college and looking to party. Jake (Tom DeNucci) invites them to his work for a fiesta of his own. Innocent mischief turns a naughty night of sex, drugs and rock and roll into an evening of pure terror. Barbed wire fences are meant to keep people OUT. But these fences keep people IN. Eric Roberts plays the role of Walter, a former black operative with an evil secret. Walter, along with his faithful brother at arms, Trevor (Michael Berryman), has some unfinished business with a seedy underworld grifter, Jonah(Jonathan Silverman). Black market business mixes with pleasure when Jake and his pals stumble upon this heinous covert operation.
Verdi stated, "Making four films over the last 24 months is one thing, but selling all four films and having the success they are receiving is simply mind blowing." Verdi added, "the landscape of filmmaking is changing daily. It's all about distribution and being able to get your product in front of as many people as possible and as quickly as possible, that's what Screen Media brings to the table. The days of small independent films spending tens of millions of dollars for their films to hit theaters is long gone. It was replaced by VOD and the ability of streaming video both at home and on handheld devices. Our goal was met when we received a national VOD release that reached over 100 million homes for both Inkubus and Loosies. That is what Screen Media was able to do with our first film Inkubus through Universal and what IFC did with Loosies.
Woodhaven released Inkubus, a slasher flick starring horror icon Robert Englund (the original Freddy Krueger), in theaters last Halloween to sell-out crowds. DVDs hit stores nationwide February 21st. The film has now sold more than 100 thousand units through outlets like Wal-Mart, RedBox, and Amazon and is currently on VOD.
The Woodhaven Production Company, a subsidiary of Verdi Productions, is a fully funded film production company, covering all aspects of filmmaking from conception of script through post production.
For further information please contact woodhavenproductioncompany@gmail.com or visit Woodhaven on the web at www.woodhavenfilms.com.
Follow "INKUBUS" on Facebook and Twitter: www.facebook.com/inkubusmovie or www.twitter.com/inkubusthemovie
Rock and Shock info: http://rockandshock.com
Like INFECTED and SELF STORAGE on Facebook
http://www.facebook.com/Selfstoragethemovie?fref=ts
http://www.facebook.com/Infectedthemovie?fref=ts
http://www.imdb.com/name/nm3838148/
http://www.imdb.com/name/nm40900
Contact Information
Chad A. Verdi
CEO
http://www.imdb.com/name/nm3838148/
Michelle L. Verdi
Music and Talent Supervisor Media
http://www.imdb.com/name/nm4090091
Media contact:
Tony Verdi
Director of Communications
401.225.7800
Chad A. Verdi
Producer
President, Verdi Productions & The Woodhaven Production Company
253 Main Street
East Greenwich, RI 02818
Verdifilms.com
Woodhavenfilms.com

Monday, October 01, 2012

Ceradyne (NasdaqGS: CRDN) Makes NASDAQ Top Gainer List on 3M Acquisition

New York, New York - October 1, 2012 (www.investorideas.com newswire) Investorideas.com staff: Investorideas.com, an investor research portal specializing in sector for independent investors reports on the top percentage gainer on the NASDAQ for Monday October 1 st. Ceradyne Inc. (NasdaqGS: CRDN) leads NASDAQ, trading at $34.92, gaining $10.49 or 42.94% as of 1:45PM EDT on over 12.4 Million shares. The stock moved on news of a takeover by 3M (NYSE:MMM).
3M (MMM) and Ceradyne, Inc. (CRDN) announced today that they have entered into a definitive agreement for 3M’s acquisition of Ceradyne, Inc. for $35.00 per share. The proposed transaction has an aggregate value of approximately $860 million, or approximately $670 million net of cash, cash equivalents, short-term investments and debt acquired.
Investorideas.com Newswire About NASDAQ
http://www.nasdaq.com/
About InvestorIdeas.com:

InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and access our 13 online stock directories 24/7 - water, renewable energy, mining stocks and more…
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com

Biodefense Stock Trading Alert: PositiveID (OTCBB: PSID) Up 15%

New York, NY - October 1, 2012 (Investorideas.com Newswire, www.biodefensestocks.com) Investorideas.com, a leader in research for independent investors issues a trading alert for biodefense stock, PositiveID Corporation (OTCBB: PSID), trading up at $0.0260, gaining 0.0035 or 15.56% as of 11:16AM EDT on over 758,000 shares. The stock had a morning high of $0.0270.
Last week the Company released an update to shareholders on its pursuit of BioWatch Generation 3, Phase II. Two weeks ago, the Department of Homeland Security ("DHS") revised its procurement strategy for BioWatch Generation 3, Phase II, which now will consist of a two-stage procurement which includes two to three years of testing estimated at $89 million. A draft request for proposal ("RFP") on this effort is scheduled for release in the fourth quarter of calendar 2012. PositiveID's patented M-BAND biodetector was developed under a competitive award from the DHS Science & Technology Directorate ("S&T").
Investorideas.com Newswire About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.www.PositiveIDCorp.com.

About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Get free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer /Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. .More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: PositiveID Corporation compensates Investorideas.com for news release publication, syndication on blogs and related sites and email distribution and company profile: renewed July 2012 -3500 cash and five hundred thousand shares for three months http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Contact
PSID:
Allison Tomek
561-805-8000
atomek@positiveidcorp.com
Investorideas.com:
Contact: 800 665 0411